DRAFT Agenda 01/25/05
FOOD AND DRUG ADMINISTRATION
TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES
ADVISORY
COMMITTEE
February 8, 2005
Hilton Hotel
8727
Colesville Road
Silver
Spring, MD
8:00 a.m. Administrative Remarks (10’)
8:10 Opening Remarks
Chairperson (10’)
8:30 Informational Presentation
Update
on BSE surveillance in the U.S. (10’) Lisa Ferguson, DVM, USDA
8:55
8:40 Topic # 1 - Possible vCJD Risk from
Investigational Coagulation Factor XI Manufactured in the 1990’s from Plasma of
Donors Residing in the United Kingdom
A.
Introduction (10’) M.
Weinstein, Ph.D., OBRR, FDA
B.
Elements of TSE risk
assessments and risk assessment for
U.K. FXI (45’) S. Anderson, Ph.D., OBE,
FDA
C.
Current public health
recommendations on management of surgical instruments used on patients with TSE
or TSE risk (10’) Lynne Sehulster, Ph.D., CDC
9:45 Open public hearing (15’)
10:00 Committee
Discussion and Vote (40’)
10:40 Break (20’)
11:00 Topic # 2 – Risk Assessment Models for Potential Risk of
Exposure to variant Creutzfeldt-Jakob Disease (vCJD) Agent in Plasma Products
A.
Introduction – rationale for
risk assessments; question to committee (10’) D. Scott, M.D., OBRR, FDA
B.
Risk Assessment – U.K. plasma
derivatives
Risk assessment
methods and assumptions and U.K. actions based on risk assessment (40’)
Kate Soldan, Ph.D., and Anna Molesworth, MSc, U.K. Health Protection Agency
C.
Preliminary Risk Assessment –
U.S.
i.
Potential TSE clearance steps
in U.S. products - FVIII, FIX, IGIV (10’) D. Scott, M.D., OBRR, FDA
ii.
Risk Assessment Model for
U.S. plasma derivatives (40’) Steve Anderson, Ph.D., OBE, FDA
12:40 Questions for
speakers (10’)
12:50 Lunch
1:50 Open Public
Hearing (40’)
2:30 p.m. Committee Discussion and Vote (45’)
3:15 Break
3:25 Topic # 3 – Potential Deferral of Blood and
Plasma Donors for History of Transfusion in European Countries
A.
Introduction (10’) A.
Williams, Ph.D., OBRR, FDA
B.
Epidemiology of vCJD in
France and risk assessments for blood and plasma derivatives (25’) Dr. Jean-Philippe Brandel, Neurologist, Epidemiosurveillance Network
C.
Estimates of blood-borne vCJD
risk in the U.K. and other European populations (20’) Sheila M. Bird, M.A.,
Ph.D, Medical Research Council Biostatistics Unit, Institute of Public Health,
Cambridge University, UK
D.
Risks and benefits of
deferring donors transfused in France and other European countries: potential
impact on blood and plasma supplies, and presentation of question for the
committee (20’) A. Williams, Ph.D.
4:40 Open public hearing (20’)
5:00 Committee Discussion and Vote
(35’)
5:35 p.m. Adjourn